We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Immunoassay Analyzer Introduced at 2016 AACC Annual Meeting

By LabMedica International staff writers
Posted on 12 Aug 2016
The recently renamed medical instrument manufacturer Siemens Healthineers (Erlangen, Germany) chose the July 31 - August 4, 2016, AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA) as the venue for introducing its new Atellica Solution automated immunoassay and clinical chemical analyzer system.

In May 2016, Siemens Healthcare changed its name to Healthineers, a name that embodied the company’s pioneering spirit and engineering expertise in the healthcare industry. More...
It is unique and bold name and gives a new identity to the organization and to its employees who serve and inspire healthcare providers worldwide.

One of Healthineers' dynamic new products is the Atellica Solution. This highly flexible immunoassay and clinical chemistry solution features patented bi-directional magnetic sample-transport technology that allows the system to operate 10 faster than conventional conveyors. The platform boasts a multi-camera vision system and intelligent sample routing that allows independent control over every sample from routine assays to STATs.

Atellica Solution, which can handle more than 30 sample container types including pediatric and special containers, can be used as a stand- alone instrument, or it can be scaled up to 10 components with more than 300 customizable configurations. The system supports remote-access monitoring and control, which maximizes instrument uptime, with a broad and expanding assay menu using proven detection technologies.

"We engineered the Atellica Solution based on our customers' needs and extensive research of market trends," said Franz Walt, president of laboratory diagnostics at Siemens Healthineers. "The result is a game-changer that delivers control and simplicity, so our customers can focus on driving better business and clinical outcomes and spend less time managing operations."

The Atellica Solution is currently being evaluated by the Food and Drug Administration and is not yet available in the United States.

Related Links:
Siemens Healthineers
AACC Annual Meeting & Clinical Lab Expo

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.